Summary
Gilead Sciences, Inc. (GILD) announced on February 21, 2011, its entry into a definitive Agreement and Plan of Merger to acquire Calistoga Pharmaceuticals, Inc. This acquisition, valued at $375 million in cash upfront with potential for an additional $225 million in milestone payments, positions Gilead to significantly expand its pipeline in antiviral therapeutics, specifically targeting hepatitis C. The acquisition of Calistoga, a development-stage company with a promising BTK inhibitor, is a strategic move to bolster Gilead's presence in a key therapeutic area with significant growth potential. The transaction is expected to close in the second quarter of 2011, subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance. The acquisition does not require the approval of Gilead's stockholders, streamlining the process. This move underscores Gilead's commitment to strategic acquisitions to enhance its product portfolio and maintain its leadership in antiviral drug development.
Key Highlights
- 1Gilead Sciences, Inc. entered into a definitive agreement to acquire Calistoga Pharmaceuticals, Inc. for $375 million in cash, with up to an additional $225 million in potential milestone payments.
- 2The acquisition aims to enhance Gilead's pipeline in antiviral therapies, particularly in the development of treatments for hepatitis C.
- 3Calistoga Pharmaceuticals is a development-stage company with a promising Bruton's tyrosine kinase (BTK) inhibitor.
- 4The transaction is expected to close in the second quarter of 2011.
- 5Closing of the merger is subject to customary conditions, including antitrust clearance under the Hart-Scott-Rodino Act.
- 6The acquisition does not require approval from Gilead's stockholders.
- 7This strategic acquisition demonstrates Gilead's commitment to inorganic growth and expanding its leadership in key therapeutic areas.